|| || |Clinical Study Confirms Exceptional Performance and High Tolerability| |Knokke-Heist (Belgium), 8 April 2025, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), a leader in dental consumer goods and professional dental consumables, announces that it has successfully advanced to Phase 3 in the development of its innovative Alginate-Organic Olive-oil based Denture Fixative Cream following a positive clinical-dermatological application study conducted by Dermatest GmbH (Germany).| |The study assessed the product’s efficacy and safety after daily application over five consecutive days by healthy denture wearers.| |The primary objective of the study was to evaluate the retention, stability, and functional benefits of the Alginate-Organic Olive-oil based Denture Fixative Cream while also investigating its tolerability according to stringent clinical-dermatological test criteria.| |The results were highly encouraging, demonstrating that Alginate-Organic Olive-oil based Denture Fixative Cream significantly improves masticatory ability and provides long-lasting retention for upper dentures, with holding times of up to 24 hours when applied according to instructions.| |Additionally, the study confirmed the excellent tolerability of the product. All participants completed the five-day application period without experiencing any adverse reactions, such as irritation or allergic responses.| |These findings underscore the unique positioning of bonyf’s Alginate-Organic Olive-oil based Denture Fixative Cream as a superior solution in the market—offering both extended hold performance and a healthy, organic-based formulation.| |*“The successful outcome of this study is a significant milestone for bonyf, as we continue our mission to develop cutting-edge solutions that enhance the well-being of denture wearers”*, said CEO, Jean-Pierre Bogaert.| |bonyf remains committed to innovation and plans to accelerate preparations for market launch, with Alginate-Organic Olive-oil based Denture Fixative Cream poised to set a new standard in denture care.| |For more information, visit bonyf.com or contact investor@bonyf.com.| |bonyf’s strengths Products with patented formulations Produced in Switzerland compliant with stringent international quality regulations Proven clinical efficacy Commercial presence in 37 countries Prospects for solid growth and rapid profitability A fast-growing oral and dental care market | || |About bonyf Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market. For more information about bonyf and its innovative oral care products, please visit www.bonyf.com. | |bonyf Jean-Pierre Bogaert investor@bonyf.com|
bonyf Advances to Phase 3 in the Development of
|| || |Clinical Study Confirms Exceptional Performance and High Tolerability| |Knokke-Heist (Belgium), 8 April 2025, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), a leader in dental consumer goods and professional dental consumables, announces that it has successfully advanced to Phase 3 in the development of its innovative Alginate-Organic Olive-oil based Denture Fixative Cream following a positive clinical-dermatological application study conducted by Dermatest GmbH (Germany).| |The study assessed the product’s efficacy and safety after daily application over five consecutive days by healthy denture wearers.| |The primary objective of the study was to evaluate the retention, stability, and functional benefits of the Alginate-Organic Olive-oil based Denture Fixative Cream while also investigating its tolerability according to stringent clinical-dermatological test criteria.| |The results were highly encouraging, demonstrating that Alginate-Organic Olive-oil based Denture Fixative Cream significantly improves masticatory ability and provides long-lasting retention for upper dentures, with holding times of up to 24 hours when applied according to instructions.| |Additionally, the study confirmed the excellent tolerability of the product. All participants completed the five-day application period without experiencing any adverse reactions, such as irritation or allergic responses.| |These findings underscore the unique positioning of bonyf’s Alginate-Organic Olive-oil based Denture Fixative Cream as a superior solution in the market—offering both extended hold performance and a healthy, organic-based formulation.| |*“The successful outcome of this study is a significant milestone for bonyf, as we continue our mission to develop cutting-edge solutions that enhance the well-being of denture wearers”*, said CEO, Jean-Pierre Bogaert.| |bonyf remains committed to innovation and plans to accelerate preparations for market launch, with Alginate-Organic Olive-oil based Denture Fixative Cream poised to set a new standard in denture care.| |For more information, visit bonyf.com or contact investor@bonyf.com.| |bonyf’s strengths Products with patented formulations Produced in Switzerland compliant with stringent international quality regulations Proven clinical efficacy Commercial presence in 37 countries Prospects for solid growth and rapid profitability A fast-growing oral and dental care market | || |About bonyf Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market. For more information about bonyf and its innovative oral care products, please visit www.bonyf.com. | |bonyf Jean-Pierre Bogaert investor@bonyf.com|
Top 10 Most Recent News Articles
Arclin's Bold Bet: Expanding Nomex Capacity in Spain
Arclin's Strategic Move for Nomex® Expansion Looks like Arclin’s not messing around. They're throwing some serious cash down in Asturias, Spain, to ramp up production of Nomex®—a material hotter than a blacktop in July with demand surging across aerospace, electric vehicles, and defense sectors. "When we bought the Nomex® business, we committed to investing in its...
Continue Reading
Unicycive Faces Stock Plunge and Legal Woes After FDA Setback
Unicycive's Rough Ride: Not Just a Bump Picture this: Your stock takes a nosedive over 39% in a day, just after a critical drug application gets slammed by the FDA—for the second time. That’s the story with Unicycive Therapeutics, Inc., ticker NASDAQ: UNC, a company that's been handing out one nail-biting moment after another to its investors. It's not just a minor...
Continue Reading
ELEGOO's M1 Ultra: Bridging Gap in 3D Scanning Tech
A Leap in 3D Scanning: Say Hello to M1 Ultra ELEGOO isn't just fiddling with a toy here—this Shenzhen-based juggernaut is rolling out the M1 Ultra on October 29, 2026, and it's causing quite a stir. While the stock market doesn't see immediate tremors from every shiny new gadget, there’s something to say when a company that pulled over $300 million in sales last year...
Continue Reading
Side Bolsters Art Division with Roboto Acquisition
Breaking Into China's Game Art Market The gaming industry's latest buzz centers around Side's acquisition of Roboto Entertainment, a boutique art studio known for crafting immersive game environments. This isn't just another headline grab—this move puts Side smack dab in the heart of China's burgeoning game market with a fresh Chengdu base. Expansion With Strategic...
Continue Reading
S&T Bancorp Hits Record Highs in Q3 2026
Surpassing Expectations with Record Metrics Well, if it isn’t another stellar quarter for S&T Bancorp (NASDAQ:STBA). The folks over in Indiana, PA, just threw down some serious numbers. The third quarter of 2026 saw net income climbing to $38.6 million, up from $36.6 million last quarter. That's a decent hike if you ask me. But what really stole the spotlight here was...
Continue Reading
Savarese Joins RID to Drive Diagnostic Innovation
A Seasoned Leader Bolsters RID's Ambitions Mario Savarese has joined Rapid Infection Diagnostics Inc.'s Strategic Advisory Board, and let me tell ya, this move's got potential. Appointing a heavyweight like Savarese as an advisor isn’t just a nod to his hefty resume. It’s about vaulting a burgeoning company into the big leagues. He's got over 20 years steering a ship...
Continue Reading
Tairex's AI System Targets Global Healthcare Gaps
AI Meets Human Expertise in Clinical Decision-Making Look, in the labyrinth of healthcare, we’re seeing a revolution with AI stepping in—not to replace the doctor, but to stand alongside them like a trusty assistant. Tairex, from the halls of Tsinghua University's Institute for AI Industry Research (AIR), has thrown its hat into this ring by unveiling their...
Continue Reading
Montega Kicks Off Agilyx Sponsored Equity Research
A Fresh Take on Agilyx's Market Standing Alright, folks. Agilyx ASA just got a new ticket for the analytical rodeo as Montega AG dives into sponsored equity research on the company. For those who aren't fluent in the arcane dialect of stock enthusiasts like yours truly, this means Agilyx now has another sharp set of eyes evaluating their every move, and let me tell you,...
Continue Reading
Nel ASA Welcomes Morten Holum as New CEO by 2027
Nel ASA's New Leader Announced In the latest shake-up at Nel ASA (OSE: NEL), Morten Holum is getting ready to take the reins as CEO. By May 1, 2027, Holum will step into the shoes left by Håkon Volldal. And folks, this isn't your average leadership swap. Holum brings a hefty toolkit to this hydrogen powerhouse, having been part of the action across the hydrogen value...
Continue Reading
Amcor's Q3 2026 Results Loom: What's at Stake?
Anticipation Builds for Amcor's Q3 2026 Financials Well, here we are again, staring down the barrel of another quarterly earnings report from Amcor plc (NYSE: AMCR). They've circled November 4th, 2026, in red on their calendars to dish out the numbers after the U.S. market's last bell rings. Investors, analysts, and the peanut gallery will be tuning in, and why not? At a...
Continue ReadingTop 5 Most Recently Viewed Articles
Ontex Group to Announce Shareholding Details Soon
Significant Shareholding Notification by Ontex Group NV Ontex Group NV is committed to transparency and compliance with regulatory requirements. Recently, the company disclosed a significant shareholding notification that it received regarding Black Creek Investment Management Inc. This notification aligns with the Belgian Law concerning significant shareholdings in...
Continue Reading
TriNet Set to Announce First Quarter Results Soon
TriNet's Upcoming Financial Report Announcement TriNet (NYSE: TNET), a prominent provider of human resources solutions tailored for small and medium-sized businesses (SMBs), is gearing up to reveal its financial results for the first quarter previously ended on March 31. The announcement is set to take place before the U.S. market opens on April 25. Details of the...
Continue Reading
PTC Therapeutics: Upcoming Q3 2025 Financial Results Call
PTC Therapeutics Plans Third Quarter 2025 Financial Call PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that it will host a conference call to discuss its financial results for the third quarter of 2025. This upcoming event is set to take place on November 4 at 4:30 p.m. ET. It promises to provide valuable insights into the company's performance and strategic...
Continue Reading
Enhancing Maritime Safety with PntGuard™ Against Spoofing Threats
Introducing PntGuard™ for Enhanced Maritime Security PntGuard™ is a revolutionary maritime-security solution designed to protect vessels from the dangers of GNSS spoofing and jamming. As the maritime sector faces growing threats from malicious disruptions of GNSS signals, PntGuard™ stands as a beacon of reliability, ensuring crews can navigate with confidence. This...
Continue Reading
Scienture Holdings Expands Market Reach with Arbli™ Agreements
Scienture Holdings Enhances Healthcare Access with New Agreements Signifying a potential reach into about 20% of the U.S. institutional market, Scienture Holdings, Inc. (NASDAQ: SCNX) is paving the way for Arbli™ (losartan potassium) across a range of healthcare facilities. The U.S. losartan market, valued at $256 million annually, witnesses around 71 million...
Continue Reading